Attention Getter: Shire Looks To Vyvanse With Adderall XR Generics In Full Force
This article was originally published in The Pink Sheet Daily
The drug maker awaits labeling decision from the FDA for its ADHD candidate Intuniv after receiving a "complete response" letter.
You may also be interested in...
In just a few weeks, schools will close for summer, a time when parents and caregivers have less reason to ensure many children are taking ADHD medications
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.